Liora Schultz is a Clinical Assistant Professor in Pediatric Hematology Oncology at Stanford University, pursuing immunotherapy research with a focus on translating cellular therapies to pediatric hematologic malignancies. During her clinical training at Memorial Sloan Kettering Cancer Center, she constructed an AML specific CD33 targeting-CAR and demonstrated its ability to eradicate AML cells. This CAR is currently undergoing clinical development. She subsequently studied effects of T cell subsets on CAR efficacy and introduced a method to skew CAR manufacturing towards naive T cells and explored methods to abrogate the inhibitory effect of T-regulatory cells. As the clinical experience with mono-specific CAR therapy has amassed, antigen downregulation has surfaced as a dominant mechanism of resistance. To address this, under the mentorship of Crystal Mackall, they developed a Phase I study of bivalent CD19/CD22 targeting CAR T cells in B-ALL and a Phase 1b trial studying CD22 targeting CAR T cells, where she serve as respective clinical lead and PI. Additionally, in efforts to understand the true functionality of CAR T cells in the ‘real world’ setting, she founded and directs the PRWCC.